Payment overview · 2025
General Payments
$242.78
15 reported records · 6 companies
Healthcare provider profile · identity verified
Thomas James Davis, MD
Allopathic & Osteopathic Physicians|Family Medicine · OAKDALE, LA · NPI 1548320161
Verified facts
What the public records show
CMS Open Payments records show Thomas James Davis, MD received $242.78 in general payments during 2025 across 15 reported records.
Lilly USA, LLC accounted for 35.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $85.07 | 35.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.03 | 31.3% | 5 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.65 | 13.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.66 | 6.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.06 | 6.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.31 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $242.78 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $63.02 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.00 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.00 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $48.70 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $33.65 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 209 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 176 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
95 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
80 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
209 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
176 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1142 | 215 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1135 | 190 |
| Sertraline Hcl | Sertraline Hcl | 760 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 595 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 585 | 120 |
| Pantoprazole Sodium | Pantoprazole Sodium | 555 | 103 |
| Lisinopril | Lisinopril | 483 | 95 |
| Gabapentin | Gabapentin | 465 | 75 |
| Metformin Hcl | Metformin Hcl | 461 | 100 |
| Losartan Potassium | Losartan Potassium | 452 | 82 |
| Omeprazole | Omeprazole | 416 | 90 |
| Furosemide | Furosemide | 398 | 88 |
| Tamsulosin Hcl | Tamsulosin Hcl | 353 | 66 |
| Clopidogrel | Clopidogrel Bisulfate | 348 | 56 |
| Methylprednisolone | Methylprednisolone | 335 | 185 |
| Allopurinol | Allopurinol | 317 | 62 |
| Tramadol Hcl | Tramadol Hcl | 279 | 63 |
| Amitriptyline Hcl | Amitriptyline Hcl | 274 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 257 | 39 |
| Potassium Chloride | Potassium Chloride | 257 | 61 |
| Carvedilol | Carvedilol | 255 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 254 | 47 |
| Glimepiride | Glimepiride | 251 | 49 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 220 | 46 |
| Donepezil Hcl | Donepezil Hcl | 218 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 218 | 33 |
| Eliquis | Apixaban | 213 | 29 |
| Meloxicam | Meloxicam | 210 | 56 |
| Jardiance | Empagliflozin | 209 | 32 |
| Spironolactone | Spironolactone | 203 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 188 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 184 | 62 |
| Ozempic | Semaglutide | 176 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 175 | 38 |
| Memantine Hcl | Memantine Hcl | 169 | 23 |
| Alendronate Sodium | Alendronate Sodium | 153 | 28 |
| Trazodone Hcl | Trazodone Hcl | 152 | 28 |
| Metformin Hcl Er | Metformin Hcl | 149 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 146 | 27 |
| Celecoxib | Celecoxib | 144 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 142 | 18 |
| Finasteride | Finasteride | 138 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 134 | 30 |
| Cefdinir | Cefdinir | 133 | 91 |
| Famotidine | Famotidine | 132 | 34 |
| Levetiracetam | Levetiracetam | 130 | 12 |
| Clonazepam | Clonazepam | 129 | 20 |
| Ezetimibe | Ezetimibe | 127 | 27 |
| Nifedipine Er | Nifedipine | 122 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 121 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 120 | 24 |
| Risperidone | Risperidone | 119 | 16 |
| Mirtazapine | Mirtazapine | 104 | 17 |
| Benazepril Hcl | Benazepril Hcl | 103 | 15 |
| Montelukast Sodium | Montelukast Sodium | 100 | 20 |
| Atenolol | Atenolol | 99 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 98 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 39 |
| Linzess | Linaclotide | 95 | 16 |
| Estradiol | Estradiol | 94 | 21 |
| Mupirocin | Mupirocin | 91 | 59 |
| Prednisone | Prednisone | 89 | 61 |
| Buspirone Hcl | Buspirone Hcl | 86 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 36 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 82 | 66 |
| Eszopiclone | Eszopiclone | 82 | 13 |
| Farxiga | Dapagliflozin Propanediol | 80 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 80 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 12 |
| Clonidine Hcl | Clonidine Hcl | 79 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 18 |
| Simvastatin | Simvastatin | 78 | 14 |
| Myrbetriq | Mirabegron | 77 | suppressed |
| Azithromycin | Azithromycin | 73 | 53 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 72 | 50 |
| Divalproex Sodium | Divalproex Sodium | 72 | suppressed |
| Chlorthalidone | Chlorthalidone | 70 | 12 |
| Trulicity | Dulaglutide | 70 | 15 |
| Baclofen | Baclofen | 69 | suppressed |
| Lorazepam | Lorazepam | 69 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 64 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 61 | suppressed |
| Bupropion Xl | Bupropion Hcl | 61 | 13 |
| Xarelto | Rivaroxaban | 61 | suppressed |
| Mounjaro | Tirzepatide | 60 | 12 |
| Synthroid | Levothyroxine Sodium | 58 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | suppressed |
| Pregabalin | Pregabalin | 56 | suppressed |
| Ondansetron Odt | Ondansetron | 55 | 31 |
| Breo Ellipta | Fluticasone/Vilanterol | 54 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 54 | 32 |
| Meclizine Hcl | Meclizine Hcl | 54 | 27 |
| Nystatin | Nystatin | 54 | 31 |
| Ranolazine Er | Ranolazine | 54 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 13 |
| Rybelsus | Semaglutide | 50 | suppressed |
| Entresto | Sacubitril/Valsartan | 49 | 11 |
| Lovastatin | Lovastatin | 49 | 11 |
| Naproxen | Naproxen | 48 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 19 |
| Novolin R | Insulin Regular, Human | 46 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | suppressed |
| Fluconazole | Fluconazole | 41 | 28 |
| Doxazosin Mesylate | Doxazosin Mesylate | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 13 |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Humulin R | Insulin Regular, Human | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 38 | suppressed |
| Ketoconazole | Ketoconazole | 37 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 37 | suppressed |
| Clotrimazole | Clotrimazole | 36 | 24 |
| Valsartan | Valsartan | 36 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Vascepa | Icosapent Ethyl | 35 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 32 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 32 | suppressed |
| Lubiprostone | Lubiprostone | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | 11 |
| Alprazolam | Alprazolam | 31 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 22 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 31 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 21 |
| Levofloxacin | Levofloxacin | 30 | 19 |
| Olanzapine | Olanzapine | 30 | suppressed |
| Rexulti | Brexpiprazole | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 15 |
| Cefuroxime | Cefuroxime Axetil | 29 | 20 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 29 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 28 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 28 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 27 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Brilinta | Ticagrelor | 26 | suppressed |
| Multaq | Dronedarone Hcl | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | suppressed |
| Ingrezza | Valbenazine Tosylate | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 22 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 22 | 15 |
| Ramipril | Ramipril | 22 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Rivastigmine | Rivastigmine | 19 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 16 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 16 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Phenytoin | Phenytoin | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Cilostazol | Cilostazol | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Dotti | Estradiol | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lamivudine Hbv | Lamivudine | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Piroxicam | Piroxicam | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
| Zypitamag | Pitavastatin Magnesium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $242.78 · 15 records | Lilly USA, LLC | BREZTRI, FANAPT, JARDIANCE, MOUNJARO, NEXLETOL, Ozempic, Rybelsus, VRAYLAR, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error